Literature DB >> 12944511

Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice.

Nicolas Champtiaux1, Cecilia Gotti, Matilde Cordero-Erausquin, Denis J David, Cédric Przybylski, Clément Léna, Francesco Clementi, Milena Moretti, Francesco M Rossi, Nicolas Le Novère, J Michael McIntosh, Alain M Gardier, Jean-Pierre Changeux.   

Abstract

Nicotinic acetylcholine receptors (nAChRs) expressed by dopaminergic (DA) neurons have long been considered as potential therapeutic targets for the treatment of several neuropsychiatric diseases, including nicotine and cocaine addiction or Parkinson's disease. However, DA neurons express mRNAs coding for most, if not all, neuronal nAChR subunits, and the subunit composition of functional nAChRs has been difficult to establish. Immunoprecipitation experiments performed on mouse striatal extracts allowed us to identify three main types of heteromeric nAChRs (alpha4beta2*, alpha6beta2*, and alpha4alpha6beta2*) in DA terminal fields. The functional relevance of these subtypes was then examined by studying nicotine-induced DA release in striatal synaptosomes and recording ACh-elicited currents in DA neurons fromalpha4, alpha6, alpha4alpha6, and beta2 knock-out mice. Our results establish that alpha6beta2* nAChRs are functional and sensitive to alpha-conotoxin MII inhibition. These receptors are mainly located on DA terminals and consistently do not contribute to DA release induced by systemic nicotine administration, as evidenced by in vivo microdialysis. In contrast, (nonalpha6)alpha4beta2* nAChRs represent the majority of functional heteromeric nAChRs on DA neuronal soma. Thus, whereas a combination of alpha6beta2* and alpha4beta2* nAChRs may mediate the endogenous cholinergic modulation of DA release at the terminal level, somato-dendritic (nonalpha6)alpha4beta2* nAChRs most likely contribute to nicotine reinforcement.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944511      PMCID: PMC6740613     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  192 in total

1.  Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior.

Authors:  B N Cohen; E D W Mackey; S R Grady; S McKinney; N E Patzlaff; C R Wageman; J M McIntosh; M J Marks; H A Lester; R M Drenan
Journal:  Neuroscience       Date:  2011-11-04       Impact factor: 3.590

2.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 3.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

5.  Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.

Authors:  Alexandre Kuryatov; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-10-05       Impact factor: 4.436

6.  Partial agonists for α4β2 nicotinic receptors stimulate dopaminergic neuron firing with relatively enhanced maximal effects.

Authors:  Ying Chen; Lisa M Broad; Keith G Phillips; Ruud Zwart
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 7.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

8.  Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via α6-containing nicotinic receptors.

Authors:  Staci E Engle; J Michael McIntosh; Ryan M Drenan
Journal:  Neuropharmacology       Date:  2014-12-04       Impact factor: 5.250

9.  The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes.

Authors:  S Rossi; S Singer; E Shearman; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

10.  Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models.

Authors:  Jun Kawamata; Syuuichirou Suzuki; Shun Shimohama
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.